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ct—Pharmaceutical firms perform R&D to develop 
and maintain core knowledge and capabilities. They 
use foundational knowledge to identify and evaluate 
relevant scientific advances and integrate those 
advances with existing knowledge and capabilities 
throughout the innovation pipeline. If core scientific 
knowledge and technical capabilities are used in this 
manner to increase innovative productivity by 
decreasing the use of other inputs, conventional 
measures of productivity based solely on outputs, per 
unit time, are likely to be inaccurate. We analyze 
productivity by examining development time and 
controlling for knowledge inputs. This approach 
measures the effect of core knowledge generated 
through pre-clinical laboratory R&D on development 
time in later stages of clinical development. We use 
patents and citations to model the use of technical 
knowledge generated through pre-clinical laboratory 
research in subsequent clinical development activities. 
Our results indicate that internally generated 
knowledge and patents, which builds on the existing 
scientific base are associated with shorter 
development times.   
 
Keywords— pharmaceutical industry; innovation; R&D; 
patents; absorptive capacity  
I. INTRODUCTION 
Pharmaceutical innovation is driven by scientific 
knowledge [1]-[4]. Research and Development (R&D) 
yields scientific advances that facilitate the discovery of 
new drug candidates and generates technical knowledge 
and capabilities that enable drug development. 
Accordingly, pharmaceutical firms perform continuous 
R&D to maintain an innovation capacity. To spur drug 
development, U.S. Federal government and 
pharmaceutical companies doubled R&D spending in the 
late 1990s [1], [3]. Stakeholders from the public and 
private sectors expected to observe more productive 
development pipelines filled with greater numbers of 
drug candidates leading to the successful development of 
greater numbers of novel drugs. However, the anticipated 
results of increased R&D spending have not been 
realized. U.S. pharmaceutical companies received 
approval from the US Food and Drug Administration 
(FDA) for fewer drug candidates in the early 2000s, 
despite increases in R&D spending, than in the early 
1990s [5]. Measures of returns to R&D spending in terms 
of the 
number of FDA approved drugs indicate stagnating 
productivity [1], [2], [5]. 
Productivity is a measure of outputs as a function of 
total inputs to development and production activities. In 
the pharmaceutical industry, R&D productivity is often 
measured using the number of drugs approved or the 
number of drug candidates successfully completing a 
phase of clinical development. Key inputs into clinical 
drug development include R&D expenditures, number of 
employees, and knowledge inputs measured as number of 
patents. Such productivity measures are based on the 
premise that knowledge is a critical input to innovation 
and productivity in the pharmaceutical industry. A firm's 
ability to develop a new drug depends on its absorptive 
capacity, which is defined by foundational knowledge 
and technical capabilities developed through continuous 
R&D [6]. Core knowledge and capabilities that 
complement new knowledge enables the effective use of 
scientific advances [6], [7]. Measures of productivity in 
the pharmaceutical industry should capture the effective 
use of knowledge to enable innovation.  
The knowledge and capabilities generated through 
core R&D are often used across multiple development 
activities, often involving multiple drug candidates [1].  
Firms use core knowledge to identify and evaluate 
relevant scientific advances and integrate those advances 
with existing knowledge and capabilities to increase 
productivity [6]. If core scientific knowledge and 
technical capabilities are used in this manner to increase 
innovative productivity by decreasing the use of other 
inputs, conventional measures of productivity based 
solely on outputs, per unit time, are likely to be 
inaccurate.  Public policies affecting pharmaceutical 
innovation based on incorrect premises are likely to be 
ineffective.  
In this paper, we analyze productivity by examining 
development time and controlling for knowledge inputs. 
This approach measures the effect of core knowledge 
generated through pre-clinical laboratory R&D on 
development time in later stages of clinical development. 
We use patents and citations to model the use of technical 
knowledge generated through pre-clinical laboratory 
research in subsequent clinical development activities. 
We use the assignee of the cited patents to differentiate 
between knowledge generated through internal R&D and 
knowledge incorporated from external sources. The novel 
approach presented here focuses on the improvements in 
development time, controlling for other inputs, derived 
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We model the effect of the firm's use of internally and 
externally generated knowledge on drug development 
time, from date of oldest patent grant to date of FDA 
approval. Patents are one measure of novel knowledge 
and technological capabilities, which have the potential to 
be developed into a marketable product [2], [4], [8], [9]. 
As in previous research, we use patents as proxies for 
technical knowledge incorporated into development 
activities. Previous studies provide empirical evidence 
that the knowledge stocks described in patents are 
associated with improved performance.1 We build on 
previous research by examining the use of scientific and 
technical knowledge to increase productivity by 
decreasing development time.  
We hypothesize that development time is negatively 
associated with the number of patents cited in the drug 
approval application. Development time is likely to be 
shorter when firms integrate more patented knowledge 
and capabilities into a development pipeline than when 
firms use less patented knowledge. We also hypothesize 
that the repeated incorporation of scientific and 
technological advances throughout the development 
process is negatively associated with development time. 
Development time is likely to decrease as the time 
between the issue of the oldest referenced patent and 
issue of the newest referenced patent  increases. 
Firms combine internally and externally generated 
knowledge in performing innovation activities. Scientific 
and technical advances that are related to the firm's core 
knowledge are more easily integrated into innovation 
activities than advances that are not related [6], [10]. 
Since knowledge and capabilities are generated in an 
evolutionary manner, the firm's core knowledge is more 
likely to complement internally generated advances than 
externally generated advances [4], [6]. Firms are more 
likely to have to conduct additional foundational research 
to enable the use of externally generated knowledge.   
We hypothesize that development time is negatively 
associated with the use of internally generated 
knowledge.  Development time is likely to be shorter 
when firms integrate more internally generated 
knowledge and capabilities into a development pipeline 
than when more externally generated knowledge is used.  
A patent's citations to prior art identify the knowledge 
that was utilized in the conception and development of 
the patented invention [8]. A greater number of citations 
to prior patents indicates a stronger connection to existing 
scientific knowledge and technical capabilities [9], [12], 
[13]. In using such patents, firms build on a more robust 
scientific and technological base.    
We hypothesize that development time is likely to be 
negatively associated with the strength of a patent's 
connection to the scientific and technological base. 
Development time is likely to be shorter when firms 
                                                
1 Firm performance has been measured as sales, market value, 
profitability,  and number of new products [2, 4, 11, 12]. 
utilize patents that are strongly connected to the scientific 
base than when patents that are less strongly connected to 
the scientific base are used.  
More recent scientific advances are associated with 
technical uncertainty. Firms are likely to have to do 
additional research in order to apply patents that embody 
newer technical advances effectively [6], [10]. Such 
additional research is likely to result in longer 
development times.    
We hypothesize that development time is likely to be 
negatively associated with the age of the knowledge cited 
by the patent as prior art. Development time is likely to 
be shorter when firms integrate patented technical 
advances that build on older knowledge and technology 
than when they integrate advances based on more recent 
advances.   
Patents are novel inventions with the potential to be 
developed into a marketable product. In more novel 
patents, knowledge and capabilities are used in a broader 
range of applications that may be developed 
commercially [9]. In previous research, the number of 
novel components, delineated in the patent's claims, was 
positively correlated with the likelihood that a patent 
would be commercialized [12]. Broader patents, which 
make more claims, are associated with greater 
commercial opportunity. We build on this research by 
examining the association between the breadth of novel 
claims made by a patent and the time to develop the 
patented technology into an FDA approved drug. Broad 
patents with many claims involve more novel knowledge 
which may be more technically difficult to utilize. Firms 
may have to perform additional research to utilize the 
novel components of patents with more claims [6], [10]. 
We hypothesize that development time is positively 
associated with the number of claims. Since the patent's 
claims delineate the novel components, development time 
is likely to increase when firms utilize patents with more 
novel components.     
Pharmaceutical firms are likely to utilize knowledge 
generated by different types of entities, including 
government laboratories, universities, and other firms, 
from  around the world [1]. As set forth in the 
organizational learning theories that describe the firm's 
absorptive capacity, a firm's ability to utilize knowledge 
depends on the relatedness of the new knowledge to 
existing knowledge stocks [6], [10]. A firm's ability to 
utilize new externally generated knowledge is not likely 
to be determined by the national origin of the entity that 
generated the knowledge.   
We hypothesize that development time is not 
affected by greater reliance on knowledge generated by 
non-U.S. firms and universities. Among firms using 
externally generated knowledge, development times for 
those using knowledge generated by U.S. entities will be 
similar to those using knowledge generated by non-U.S. 
entities.  
III. DATA 
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We have created a new data set that links FDA 
approved drugs to drug-related patents.2 The analysis is 
limited to the final stages of the innovation pipeline, 
between initial patent grant and FDA approval, which 
include clinical trials and FDA review. The patents 
associated with each new drug reflect the knowledge 
inputs used in these innovation activities. These 
innovation activities are performed by the firm that is 
granted FDA approval (the focal firm). The sample 
consists of 343 new drugs developed by 194 firms and  
approved between 1985 and 2008. The drug approval 
applications included in the sample cite 252 patents. We 
obtained data on the referenced patents from the National 
Bureau of Economic Analysis Patent Database [8]. The 
date of issue for the patent used to develop a drug is 
included in the sample, and demarcates the beginning of 
this phase in the innovation pipeline.3 More than one firm 
may use the same patent to produce a new drug requiring 
FDA approval. Each firm's new drug application and 
reference to a patent reflect its first use of patented 
knowledge on a given development project, but not 
necessarily the very first use of that knowledge. We 
construct development time as the time elapsed from the  
issue date for the oldest patent referenced in the drug 
application to the FDA approval date. 
IV. ANALYTIC APPROACH  
A. Analytic Method  
We use Poisson regression models to predict 
development time, measured in months, from patent issue 
to FDA approval.4 Poisson regression models assume that 
the dependent variable takes on non-negative integer 
values, with a mean equal to the exponential of a linear 
function of explanatory variables [14]. With a Poisson 
distribution, variance is equal to a random variable's 
mean (equidispersion). The Poisson model will produce 
consistent estimates of the effects of the explanatory 
variables, even if the distribution of the explanatory 
variable is not equidispersed, as long as the expectation of 
the dependent variable conditional on the explanatory 
variables is correctly specified [15].5 Robust standard 
errors can be calculated to provide correct parameter 
variance estimates if the actual data generating process 
deviates from the equidispersion process.  We therefore 
use Poisson quasi-maximum likelihood methods, couples 
with robust standard errors, to estimate the effects of 
explanatory variables on development time in a fashion 
that minimizes distributional assumptions.  
B. Explanatory Variables  
                                                
2 We obtained data on FDA approved drugs from the FDA Orange 
Book, which can be accessed at 
www.accessdata.fda.gov/scripts/cder/ob/default.cfm 
3 We identified a firm's first use of a patent through reference to the 
patent in the FDA drug approval application.  
4 Although the patent application date may be a more relevant 
indicator of commercial and technical potential, the exact 
application date is not included in the NBER patent database. 
5 This robustness property requires that the true distribution be in the 
linear exponential family, which includes among its members the 
Poisson, negative binomial, Bernoulli, exponential, gamma, normal, 
and inverse Gaussian distributions. 
All of the drug applications used in this sample cite 
at least one patent that was used in the development of 
that drug. We use the number of patents cited in an 
application as a general measure of the amount of 
knowledge used in innovation activities. We use the time 
lag from the date on which the oldest patent was issued to 
the date on which the most recent patent was issued to 
measure the repeated incorporation of new scientific 
knowledge into development processes. Larger lags are 
indicative of the repeated  use of new advances embodied 
in patents. Some of the patents in the drug approval 
application are assigned to the focal firm, while others are 
assigned to other entities. We use the proportion of 
patents cited in the approval application that were 
assigned to the focal firm as a measure of the internal 
knowledge used to develop the drug. These patent 
variables reflect a firm's general use of scientific 
knowledge and its reliance on internally developed 
knowledge.  
We use several patent characteristics to characterize 
the knowledge inputs used in innovation activities. We 
use the number of claims made by a patent to measure the 
number of novel components in a patent and the breadth 
of knowledge and capabilities embodied in the patent. We 
use the number of citations made to patents in the prior 
art as a measure of the connection between the 
knowledge embodied in the patent and existing scientific 
knowledge. We use a patent's mean backward citation lag 
to measure the age of the knowledge used in early stage 
R&D that led to the patented invention. The citation lag 
to the prior art reflects the maturity of the knowledge and 
technologies used in pre-clinical laboratory development 
activities. These citation-based measures delineate the 
relationship between the knowledge embodied in the 
patent and the existing scientific and technological base.  
We use a series of dummy variables to distinguish 
between focal patents assigned to U.S. and foreign 
entities.6 Assignee type one refers to “unassigned” patents 
that were issued to the inventor. Information on the 
nationality of the assignee is not available, since the 
patent is not formally assigned. Assignee type two is 
comprised of U.S. non-government entities, including 
firms and universities. Assignee type three includes 
foreign non-government entities.7 The coefficients for 
each assignee type measure the effect on development 
time relative to the use of patents assigned to U.S. non-
government entities (type two).   
We control for some firm-specific characteristics that 
are likely to affect productivity. To control for firm size, 
we use the number of employees in the year before the 
firm receives FDA approval for the drug. We use the 
number of new drugs for which the firm has received 
FDA approval to control for the firm's experience in 
clinical development and managing the FDA approval 
process.  
                                                
6
 The assignee variable refers to the assignee of the focal patent. It 
does not indicate whether the patent was assigned to the company 
who developed the drug and received FDA approval.  
7 This assignee classification system is based on the USPTO assignee 
classification system [8]. It includes government agencies as 
assignees. However, none of the patents included in the sample 
were assigned to government agencies.  
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We control for the implementation of new regulatory 
policies implemented under the Prescription Drug User 
Fee Act (PDUFA). The Act was intended to improve the 
approval process by authorizing the FDA to collect user 
fees that are used to augment resources used in reviewing 
drug approval applications. The PDUFA is a dummy 
variable equal to one for drugs approved after the 
implementation act and zero for those approved before 
the act was implemented. Although regulatory policies 
are not likely to affect R&D strategies to develop 
knowledge stocks, previous research indicates that 
PDUFA has affected drug approval time [5].  
V. RESULTS 
We obtained data on a sample of 343 FDA approved 
drugs that cited patents in their drug approval 
applications.8 Development time ranged from one to 211 
months, with an average of 77.6337 months. We present 
descriptive statistics for all explanatory variables in Table 
I and a histogram illustrating the distribution of 
development times in Fig. 1.  
 
Fig. 1. Histogram depicting the distribution of drug development times 
TABLE I 
DESCRIPTIVE STATISTICS 
 Mean Standard 
Deviation  
Minimum Maximum 
Development time  77.6337 
 
48.8308 1 211.0000 
Patents per FDA 
application 
3.0029 2.4020 1 18.0000 
Time from oldest 
cited patent to most 
recent cited patent 
25.4800 36.0600 0 176 
Proportion of 
patents assigned to 
the firm  
0.5369 0.4625 0 1 
Total number or 
approved drugs  
4.1000 5.7600 0 54 
Number of claims 17.0000 13.5200 1 113 
Number of citations 
made 
8.3300 9.3600 1 63 
Citation lag from 
focal patent to cited 
prior art  
10.2400 6.2700 1 48.25 
                                                
8 The sample only includes FDA drug approval applications that cite 
patents that were issued prior to drug approval. Firms may receive 
patents for drug-related inventions issued after approval.  
Employees 
(thousands) 
32.1300 36.6195 0.0080 151.9 
Prescription Drug 
User Fee Act  
0.9700 0.1682 0 1 
Assignee type 1 0.0436 0.2045 0 1 
Assignee type 2 0.5639 0.4966 0 1 
Assignee type 3 0.3866 0.4877 0 1 
Assignee type 4 0.0058 0.0761 0 1 
 
In Table II, we present the results of the Poisson 
regression model and robust standard errors used to 
estimate the effects of the use of knowledge inputs, 
embodied in patents, on development time. The Wald test 
statistic for the overall model is significant.  The results 
indicate that the variables included in the model have a 
joint effect on development time, and thus we reject the 
null hypothesis of no joint effect. One measure of 
goodness of fit for this model is the correlation of 
predicted development times with actual development 
times [15]. The correlation is 0.1402 and statistically 
significant. Although the correlation is low, it is within 
the typical ranges for R2-like measures for models using 
micro data with substantial idiosyncratic variation across 
subjects. Thus, the knowledge inputs embodied in patents 
affect productivity, measured as development time.  
A number of patent characteristics have a statistically 
significant effect on development time (Table II). The 
regression coefficients are semi-elasticities that measure 
the proportional change in development time from a unit 
change in the covariate. We present the elasticities of 
development time associated with each explanatory 
variable in Table 3. Although the number of patents 
referenced in the FDA approval application was not 
statistically significant, the proportion of patents assigned 
to the focal firm and the lag from oldest to newest patent 
have statistically significant effects. In accordance with 
our hypothesis, a 1% increase in the proportion of 
referenced patents assigned to the focal firm is a 
associated with a 0.09% decrease in development time. 
The use of internally generated knowledge is associated 
with shorter development times. Contrary to our 
hypothesis, a 1% increase in lag from the issue date of the 
oldest patent to the issue date of the newest patent is 
associated with a 0.06% increase in development time. 
The number of citations made by the focal patent has a 
statistically significant negative effect, while the time 
from the application date of the focal patent to the issue 
date of the cited patent is not statistically significant. As 
we hypothesized, a 1% increase in the number of citations 
made is associated with a 0.07% decrease in development 
time. These results suggest that a stronger connection to 
existing knowledge decreases development time 
regardless of the age of the cited knowledge. The number 
of claims included in the patent had a statistically 
significant positive effect. In accordance with our 
hypothesis, a 1% increase in the number of claims made 
by a patent is associated with a 0.06% increase in 
development time. The observed effect suggests that the 
use of patents with greater numbers of novel elements 
increases development time. Thus, the observed results 
provide preliminary evidence that knowledge inputs can 
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be used to increase productivity by decreasing 
development time.   
Firms utilize knowledge from different sources. Of 
the 343 FDA approved drugs included in this sample, 100 
cited patents that are assigned to non-U.S. government 
entities. The dummy variable for patents assigned to 
foreign entities is not statistically significant. This lack of 
significance indicates that the national origin of the 
patented knowledge does not affect development time. 
These results provide evidence of the increasing 
international dynamics of pharmaceutical innovation and 
the diminishing importance of a national innovation 
ecosystem.   
The Prescription Drug User Fee Act had a 
statistically significant effect on drug development time. 
However, contrary to our hypothesis and previous 
research, development time increased after 
implementation of the Act. The observed increase 
indicates that changes in the bureaucratic process increase 
development and approval time. It is important to note 
that the mean approval year was 1998 and that most drugs 
were approved after the act was implemented. In future 
research, we will explore the effects of policies to 
promote pharmaceutical innovation and the impacts of 




 Coefficients  
(standard error) 
* statistically significant 
at 0.1 level  
Wald Chi-square statistic  120.8 
Constant 2.6772 * 
(0.2382) 
Patents per FDA application - 0.0093 
(0.0146) 
Time from oldest cited patent to most 
recent cited patent 
0.0025 * 
(0.0008) 
Proportion of patents assigned to the firm  - 0.1736 * 
(0.0703) 
Total number of FDA approved drugs  0.0018 
(0.0049) 
Number of claims 0.0035 * 
(0.0020) 
Number of citations made to prior art - 0.0086 * 
(0.0041) 
Citation lag from focal patent to cited 
prior art  
- 0.0077 
(0.0049) 
Number of employees  - 0.0012 
(0.0009) 
Prescription Drug User Fee Act  1.8174 *  
(0.2197)  
Assignee type 1 0.1868 
(0.1199)  
Assignee type 3 0.0914  
(0.0676)  
Assignee type 4 -0.05783 
(0.3866) 
Correlation between predicted 





We have presented empirical evidence that scientific 
knowledge and technical capabilities may be used to 
enhance R&D productivity in the pharmaceutical industry 
by decreasing development time. According to the 
organizational learning theory of absorptive capacity, 
firms use existing knowledge and technical capabilities to 
integrate new knowledge into development activities. 
Our results indicate that the utilization of patents that 
build on existing knowledge, as indicated by the number 
of citations made to the prior art, leads to shorter 
development times. Moreover, knowledge generated 
through internal R&D activities, which we identified as 
patents assigned to the firm performing clinical 
development activities, is  
TABLE III 
ELASTICITY OF DEVELOPMENT TIME 
Variables  Elasticity 
Patents per FDA application -0.0279 
Time from oldest cited patent to most 
recent cited patent 
0.0649 
Proportion of patents assigned to the firm  -0.0932 
Total number of FDA approved drugs 0.0072 
Number of claims 0.0602 
Number of citations made to prior art -0.0719 
Citation lag from focal patent to cited prior 
art  
-0.0785 
Employees  -0.0380 
Prescription Drug User Fee Act  1.76 
Assignee type 1 0.0082 
Assignee type 3 0.0352 
Assignee type 4 -0.0003 
 
associated with shorter development time. Internally 
generated knowledge constitutes a knowledge base that 
firms use to integrate new knowledge that enhances R&D 
productivity. Thus, R&D that builds on existing 
knowledge and capabilities increases productivity by 
reducing development time.  
Scientific advances lead to the development of novel 
drugs [1]. However, new knowledge does not necessarily 
enhance productivity by decreasing development time. 
Prior research has used the number of claims made by a 
patent as a quantitative indicator of the pioneering nature 
of a patented invention that was associated with an 
increased likelihood that the invention would be 
commercialized [12]. Our results show that development 
time is negatively associated with the “pioneering” nature 
of an invention. The utilization of patents with more 
novel components, identified as patent claims, increases 
development time. The positive effect of the time lag 
from the date on which the oldest patent was issued to the 
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date on which the most recent patent was issued indicates 
that development time increases with the ongoing 
incorporation of new scientific knowledge into 
development activities. Our results indicate that the use of 
more “novel” scientific knowledge increases 
development time. According to organizational learning 
theory, firms conduct additional research to enable the 
effective use of “novel” knowledge that is not related to 
their existing knowledge [6], [10]. Thus, the returns to 
basic scientific advances are likely to be realized further 
in the future because of the complexity of utilizing new 
knowledge in ongoing development activities.  
We examined the effect of the Prescription Drug User 
Fee Act, which was intended to accelerate innovation by 
providing the FDA additional resources to review 
approval applications in a timely manner. Although some 
have found that PDUFA has reduced mean development 
time, our results indicate that development time increased 
after implementation of PDUFA [5]. It is possible that 
PDUFA has decreased development time, but that the 
decrease has been outweighed by other time-variant 
factors that have increased development time. 
Nonetheless, the positive effect of PDUFA indicates that 
development time has increased. 
Our results indicate that firms use core knowledge to 
enhance R&D productivity. Accordingly, measures of 
productivity that do not account for the role of R&D in 
sustaining core competencies will be imprecise. Policies 
intended to promote innovation in the pharmaceutical 
industry should reflect the enabling role of knowledge in 
development activities. In future research, we will 
examine the effects of innovation policies on the use of 
knowledge to improve productivity. 
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